Several prominent neuroscientists (including, for example, Corey Goodman, Zach Hall and Richard Scheller) have recently left academic positions at major research institutions to take up new jobs in industry. These high-profile moves reflect a general trend toward the increasing commercialization of neuroscience, and the process has the potential to snowball as more academic researchers are tempted to make the transition. A closer relationship between industry and academia can bring many benefits to both parties, but it will be important for the academic community to prepare for the changes that are likely to ensue-especially with regard to the training of new students and the publication and dissemination of results.
Cynics may regard those who move to industry as having 'sold out' on academic freedom and creativity in the name of personal profit, but in reality there are many other factors that make the private sector an increasingly attractive career option for neuroscientists. For one thing, the level of private investment in neuroscience is growing substantially: the aging populations of many industrial countries represent a huge market for treatments for brain disease, and investment in this market seems increasingly promising as advances in basic understanding suggest new therapeutic approaches. At the same time, genomics and other high-throughput technologies present new research opportunities that can only be realized with substantial funding, on a scale that would be out of reach for most academic laboratories.
Moreover, neuroscience-perhaps more than many fieldstends to benefit from multiple levels of analysis (combining molecular and behavioral techniques, for example), which can require extensive collaboration among research groups. Such collaborations are often easier and more efficient in industry, where the management structure rewards group achievement rather than the smaller-scale individual accomplishments that are the key to career advancement in universities.
An important incentive for many researchers is the ability to continue working on an intellectually stimulating program of basic research. This is becoming increasingly feasible, as more companies adopt programs of rational drug discovery that are founded on basic biological understanding. Studies from such companies are often indistinguishable from those of academic laboratories, and industry papers describing, for example, new animal models of neural diseases or new growth factors are routinely published in the top basic science journals. Indeed, the business plan of many start-ups seems to be to make themselves an attractive target for acquisition by a larger pharmaceutical company, whose aim is to buy knowledge; the product in essence becomes the company itself.
This trend toward privatization is not confined to cellular and molecular neuroscience: systems and computational neuroscience are also starting to bear commercial fruit. For example, Joseph Atick, a former vision researcher at Rockefeller University, has established a company to make face-recognition systems, and has received considerable publicity-and a tripling of his company's stock price-in the wake of the September 11th terrorist attacks. Another vision researcher, John Daugman at Cambridge University, has developed pattern recognition algorithms that make it possible to identify people by their iris patterns; machines based on this principle are now being tested in several airports in an attempt to make security checks faster and more reliable, and the technology may have much broader applicability.
In many respects, therefore, the commercialization of basic research is a welcome trend. It provides an infusion of new funds into basic research and a mechanism by which the results of basic research can be translated into practical gains-a highly rewarding experience, but one that frequently eludes academic scientists, who routinely underestimate the huge amount of work needed to make it happen. Furthermore, companies provide an outlet for established scientists looking for new challenges, and they open up new employment opportunities for postdocs who do not wish to follow a 'traditional' academic path (or who are unable to find permanent positions as a result of the much-discussed oversupply problem).
Nevertheless, as more researchers attempt to straddle the academic world and the private sector, the scientific community should be alert to potential problems. For example, as scientists become increasingly occupied with commercial activities (which often involve extensive travel), they will clearly have less time for teaching and other less glamorous academic duties, such as serving on thesis and grant review committees. Most universities have policies that restrict outside consulting to one day per week, but such activities are difficult to monitor in practice, and enforcement is often weak. One obvious solution is for companies to take a larger role in training new students, and here neurobiology departments might do well to follow in the steps of chemistry and engineering departments. In these fields, where industry has traditionally been a common career path, companies often have significant roles in supporting training programs. Such support can come in the form of money or manpower for teaching and mentoring.
Perhaps the greatest challenge in an era of increased commercialization will be to maintain the free exchange of ideas on which the long-term health of the scientific community depends. Although many companies choose to publish their work, in order to attract both investors and employees, business interests frequently impose delays in publication, either to gain time to file patent applications or to avoid tipping off competitors to work in progress. Companies may also be reluctant to release reagents and information that would be routinely shared between academic researchers. Journals have an important role here-'publication' should mean exactly that, and anyone who wishes to claim academic credit for their work should be willing to share it in full. editorial Neuroscience, Inc.
